Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer

ABSTRACT:

SUBMITTER: Baselga J 

PROVIDER: S-EPMC3247045 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature